JAGSNPHARM.BOJAGSNPHARM.BO
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
18.45%
↓ 92% below average
Average (39q)
232.21%
Historical baseline
Range
High:4233.37%
Low:-193.46%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 18.45% |
| Q2 2025 | 85.05% |
| Q1 2025 | -52.25% |
| Q4 2024 | -3.75% |
| Q3 2024 | 52.13% |
| Q2 2024 | 304.50% |
| Q1 2024 | -24.06% |
| Q4 2023 | -70.70% |
| Q3 2023 | 23.53% |
| Q2 2023 | 6.19% |
| Q1 2023 | -22.71% |
| Q4 2022 | -27.31% |
| Q3 2022 | 122.00% |
| Q2 2022 | 2185.39% |
| Q1 2022 | -105.70% |
| Q4 2021 | -47.87% |
| Q3 2021 | 11.81% |
| Q2 2021 | 59.23% |
| Q1 2021 | -9.05% |
| Q4 2020 | 36.16% |
| Q3 2020 | 92.25% |
| Q2 2020 | 85.25% |
| Q1 2020 | -44.44% |
| Q4 2019 | 2.85% |
| Q3 2019 | 14.84% |
| Q2 2019 | -40.20% |
| Q1 2019 | 65.63% |
| Q4 2018 | -18.25% |
| Q3 2018 | 142.92% |
| Q2 2018 | 188.90% |
| Q1 2018 | 51.33% |
| Q4 2017 | 41.88% |
| Q3 2017 | -193.46% |
| Q2 2017 | 4233.37% |
| Q1 2017 | -99.24% |
| Q4 2016 | 1944.86% |
| Q3 2016 | -21.50% |
| Q2 2016 | -66.01% |
| Q1 2016 | 384.95% |
| Q4 2015 | -18.59% |